CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. [electronic resource]
Producer: 20140912Description: 136-49 p. digitalISSN:- 1878-3686
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Breast Neoplasms -- drug therapy
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Class I Phosphatidylinositol 3-Kinases
- Cyclin-Dependent Kinase 4 -- antagonists & inhibitors
- Cyclin-Dependent Kinase 6 -- antagonists & inhibitors
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- Drug Synergism
- Female
- Genetic Predisposition to Disease
- Humans
- MCF-7 Cells
- Mice
- Mice, Nude
- Mice, SCID
- Molecular Targeted Therapy
- Mutation
- Phenotype
- Phosphatidylinositol 3-Kinases -- genetics
- Phosphatidylinositol Phosphates -- metabolism
- Phosphoinositide-3 Kinase Inhibitors
- Phosphorylation
- Protein Kinase Inhibitors -- administration & dosage
- Proto-Oncogene Proteins c-akt -- antagonists & inhibitors
- RNA Interference
- Retinoblastoma Protein -- metabolism
- Signal Transduction -- drug effects
- Time Factors
- Transfection
- Treatment Outcome
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.